Radcliffe Capital Management L.P. 13D and 13G filings for SAB Biotherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 06:28 am Sale | 2023-12-31 | 13G | SAB Biotherapeutics, Inc. SABS | Radcliffe Capital Management L.P. | 0 0.000% | -62,756 (Position Closed) | Filing |
| 2022-02-14 06:09 am Purchase | 2021-12-31 | 13G | SAB Biotherapeutics, Inc. SABS | Radcliffe Capital Management L.P. | 62,756 1.440% | 62,756 (New Position) | Filing |